This acquisition brings two important development programs to our medical dermatology and aesthetics pipeline and is a prime example of our Open Science R&D model. NDS™, Anterios’ platform technology enables local, targeted delivery of botulinum toxin across the skin without injections. This technology will be developed on a global basis, so that we can bring it to patients and customers around the world. We have also acquired non-exclusive rights to Anterios’ Phase 2 program ANT-1207, a topical formulation botulinum toxin type A, for the potential treatment of hyperhidrosis (excessive sweating), acne, and crow’s feet lines.